Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine for Cognitive Deficits in Schizophrenia
NCT00463879Phase 3Completed
- Sponsor
- Yale University
- Start
- Sep 2005
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of galantamine in schizophrenia, sponsored by Yale University. Started Sep 2005; status: completed.
02
Drugs
galantamine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00463879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00463879.